A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy
Brief description of study
A5369 is a phase I/IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and efficacy of p24CE/full-length Gag DNA, as a therapeutic vaccine in HIV-1 infected persons. The study targets to enroll 40 participants. All participants are well-suppressed on ART, current CD4 T cell counts greater than 500 cells/mm3, and nadir CD4 T cell counts greater than 350 cells/mm3. Each participant will receive active vaccine/placebo at weeks 0, 4, 12, and 24 delivered by electroporation after intramuscular injection. The primary efficacy outcome will be based on HIV-specific immunologic assays at baseline and week 26.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
['HIV Infections']
-
Age: - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 830198
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
